Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Tumor Checkpoint Controller Also In Early Clinical Studies

 
• By John Davis
  
Apples
FGFR kinase inhibitors may have differences that affect efficacy and side effects. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer